NCT07471932 A Study of LAD106 in Healthy Adult Participants
| NCT ID | NCT07471932 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Almirall, S.A. |
| Condition | Healthy Volunteers |
| Study Type | INTERVENTIONAL |
| Enrollment | 93 participants |
| Start Date | 2026-02-17 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 93 participants in total. It began in 2026-02-17 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.
Eligibility Criteria
Inclusion Criteria: 1. Signed informed consent and willing and able to comply with the study protocol. 2. Healthy men or women,18 to 45 years of age (inclusive) at screening. 3. Female participants agree to use effective contraception. 4. Male volunteers agree to use barrier protection when they engage in sexual relations with women of child-bearing potential (WOCBP) or lactating women. 5. Body mass index (BMI) between 18 and 32 kilograms per square meter (kg/m\^2), inclusive, and with a minimum bodyweight of 50 kg. 6. Has the ability to communicate well with the Investigator in Dutch language and willing to comply with the study restrictions. Exclusion Criteria: 1. Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the participant in the opinion of the investigator. 2. Clinically significant abnormalities, as judged by the Investigator, in laboratory test results. 3. Use of any medications (prescription or over-the-counter \[OTC\]), within 14 days prior to IMP dosing or less than 5 half-lives (whichever is longer). An exception is made for paracetamol (up to 4 g/day). 4. If a woman, pregnant, or breast-feeding, or planning to become pregnant during the study.
Contact & Investigator
Study Director
STUDY DIRECTOR
Almirall, S.A.
Frequently Asked Questions
Who can join the NCT07471932 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Healthy Volunteers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07471932 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07471932 currently recruiting?
Yes, NCT07471932 is actively recruiting participants. Contact the research team at GCO@almirall.com for enrollment information.
Where is the NCT07471932 trial being conducted?
This trial is being conducted at Leiden, Netherlands.
Who is sponsoring the NCT07471932 clinical trial?
NCT07471932 is sponsored by Almirall, S.A.. The principal investigator is Study Director at Almirall, S.A.. The trial plans to enroll 93 participants.